Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

Merck (NYSE:MRK) announced on 7/26/18 that Keytruda, Merck’s anti-PD-1 therapy, has been approved by the China National Drug Administration (CNDA) for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy. This is the first and only approval of an anti-PD-1 therapy for advanced melanoma in China.